Article
Rituximab tunes desmoglein-3-specific follicular T cells in patients with pemphigus vulgaris
2023-04-26
Abstract excerpt
<h4>Background: </h4> : Pemphigus vulgaris (PV) is characterized by pathogenic auto-antibodies targeting interkeratinocytes desmoglein (Dsg) 1 and 3, and by the HLA-DRB1-0402 predisposition allele. Treatment using rituximab (RTX) combined with short-term corticosteroids (CS) allows disease control and long-lasting remission. The aim of this study is to evaluate the impact of RTX on the circulating subpopulations o...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5ef84b48-e5ee-55b0-959d-a7acfc0e843c
- DOI
- 10.22541/au.168252564.46952044/v1
